Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

699
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
699
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

499
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
499
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

769
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
769
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.0K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

517
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
517

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute migraine treatments in patients above age 65.

Headache·2026
Same author

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same author

Early Dynamics of Body Temperature in Acute Stroke: Insights into Outcomes and Management.

Journal of clinical medicine·2026
Same author

Linking first-pass reperfusion success to proteomic markers in large and medium vessel ischemic stroke: an exploratory study.

Precision clinical medicine·2026
Same author

In Vitro Analysis of TWEAK/Fn14 Axis in the Blood-Brain Barrier Models during Oxygen-Glucose Deprivation and Reoxygenation.

Molecular neurobiology·2026
Same author

Navigated and robotic-assisted sacroiliac joint fusion: a narrative review.

Expert review of medical devices·2026

Related Experiment Video

Updated: Dec 15, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.6K

Rituximab for Autoimmune Encephalitis with Epilepsy.

Mohankumar Kurukumbi1, Rahul H Dave1, Jose Castillo2

  • 1Department of Neurology, Inova Fairfax Hospital, Falls Church, VA, USA.

Case Reports in Neurological Medicine
|July 14, 2020
PubMed
Summary

Autoimmune encephalitis can cause difficult-to-treat epilepsy. Rituximab effectively controlled epilepsy in three patients with N-methyl-D-aspartate receptor (NMDAR), leucine-rich, glioma inactivated 1 (LGI1), or voltage-gated calcium channel (VGCC) antibodies.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.2K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.2K

Related Experiment Videos

Last Updated: Dec 15, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.6K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.2K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.2K

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Intractable epilepsy poses a significant challenge, often leading to intensive care unit (ICU) admissions.
  • Autoimmune encephalitis is an increasingly recognized, treatable cause of intractable epilepsy.
  • This condition involves antibodies targeting cerebral antigens like ion channels and neurotransmitter receptors.

Observation:

  • Three patients presented with status epilepticus refractory to standard treatments.
  • Diagnostic assays identified serum antibodies against N-methyl-D-aspartate receptor (NMDAR), leucine-rich, glioma inactivated 1 (LGI1), or voltage-gated calcium channel (VGCC).

Findings:

  • All three patients achieved complete and sustained epilepsy control following rituximab treatment.
  • Symptoms associated with their autoimmune encephalitis also improved.
  • Cell-based assays confirmed the presence of specific autoantibodies.

Implications:

  • Rituximab demonstrates significant efficacy in managing intractable epilepsy associated with specific autoantibodies.
  • This suggests rituximab as a viable therapeutic option for autoimmune encephalitis-induced epilepsy.
  • Further research into rituximab's role in neuroimmunological disorders is warranted.